PROMETHEUS
Biotech startup for regenerative medicine
__
Prometheus is an innovative biotech startup that produces and sells solutions for human and veterinary regenerative medicine. The team has developed Ematik, products for veterinary medicine, based on the use of blood derivatives (PRP – Platelet Rich Plasma) for cell and tissue regeneration.
Team Prometheus
__
CEO AND CO-FOUNDER
Riccardo Della Ragione
CTO AND CO-FOUNDER
Valentina Menozzi
CSO AND CO-FOUNDER
Alice Michelangeli
CLINICAL DIRECTOR
Gianfranco Bellezza
MECHANICAL ENGINEER
Luigi Paciello
MARKETING AND COMUNICATION
Antonio Della Ragione
Company profile
__
Prometheus is a biotech startup, operating in the field of regenerative medicine.
The team of Prometheus was founded in 2017 and is composed of Riccardo Della Ragione, Alice Michelangeli and Valentina Menozzi, with the idea of combining biotechnology and 3D printing.
The research has allowed them to develop a proprietary technology at the service of regenerative medicine, currently applied in the veterinary field.
The result of their research is Ematik Ready, a kit for the creation of a patch for the treatment of skin wounds.
Prometheus has created three products, filed three patents and raised €1 million in equity crowdfunding.
Over the years, the team has expanded to include the figures needed for the company to grow and bring the technology behind Ematik into the human sphere:
Dr Gianfranco Bellezza has taken on the role of Clinical director and Antonio Della Ragione is in charge of marketing and corporate communications, the latest to join the team is Luigi Paciello who is in charge of the engineering part of the Ematik project.
Grants & Awards
__
Bando per il Sostegno alla creazione e al consolidamento di Start up innovative 2018 D.G.R. 812/2018 - Asse 1 - Azione 1.4.1 POR-FESR 2014 - 2020
__
Prometheus is an innovative start-up that proposes Ematik, an innovative patented system consisting of a machine and a disposable kit, for the creation of an autologous and customised medicament for veterinary use, in particular for the treatment of hard-to-heal skin wounds. In less than 50 minutes, the Ematik system allows the veterinarian to develop a tailor-made medicament by combining the patient’s blood with the biopolymer mixture supplied with the disposable kit. Ematik, which can be used on animals of all sizes, is capable of accelerating and improving the healing of hard-to-heal skin wounds. The technological innovation, demonstrated by the results obtained from various clinical tests conducted on animals with chronic wounds, is given by:
– Healing times halved compared to competing products;
– Autologous personalised medicament (obtained from the patient’s own blood) and with no side effects;
– Allows the reappearance of the animal’s original fur without scarring (important aspect in high value animals);
– Antibacterial properties: reduces the risk of infection in the injured area and allows the use of antimicrobial/antibiotic substances to be reduced;
– Easy to apply and bio-absorbable from the wound;
– Fully automated and fast: Ematik, starting with the loading of the patient’s blood into the machine, allows the production of an autologous and customised medicament in just 50 minutes.
By participating in the 2018 Start up call, Prometheus aimed to optimise IoT solutions and accelerate market penetration through the acquisition of:
- Machinery and technical equipment for the production process, furniture and hardware
- Rental and hire of scientific equipment and laboratories
- Promotional expenses for website, promotional material, advertising, promotional/scientific publications, participation in trade fairs
- Technical consultancy for product and equipment optimisation
- Strategic and IP protection consultancy
The implementation of the project enabled the achievement of the planned objectives
in particular: - enhancement of the company’s IT equipment through the purchase of new hardware instruments
- enhancement of the technical and production equipment through the purchase of specific equipment and tools
- supporting investments in marketing, in particular for promotional material, participation in trade fairs (SCIVAC), implementation of a marketing campaign and optimisation of the website
- the acquisition of specialist technical consultancy, in particular for the optimisation of technical production equipment, hardware/software and aesthetic/functional optimisation of the Ematik machine and its industrialisation
- acquisition of specialist advice for the implementation of the sales network and for the protection of intellectual property by filing and extending patents abroad
PROMETHEUS
Biotech startup for regenerative medicine
Prometheus is an innovative biotech startup that produces and sells solutions for human and veterinary regenerative medicine. The team has developed Ematik, products for veterinary medicine, based on the use of blood derivatives (PRP – Platelet Rich Plasma) for cell and tissue regeneration.
Prometheus team
Company profile
Prometheus is a biotech startup, operating in the field of regenerative medicine.
The team of Prometheus was founded in 2017 and is composed of Riccardo Della Ragione, Alice Michelangeli and Valentina Menozzi, with the idea of combining biotechnology and 3D printing.
The research has allowed them to develop a proprietary technology at the service of regenerative medicine, currently applied in the veterinary field.
The result of their research is Ematik Ready, a kit for the creation of a patch for the treatment of skin wounds.
Prometheus has created three products, filed three patents and raised €1 million in equity crowdfunding.
Over the years, the team has expanded to include the figures needed for the company to grow and bring the technology behind Ematik into the human sphere:
Dr Gianfranco Bellezza has taken on the role of Clinical director and Antonio Della Ragione is in charge of marketing and corporate communications, the latest to join the team is Luigi Paciello who is in charge of the engineering part of the Ematik project.
Grants & Awards
Bando per il Sostegno alla creazione e al consolidamento di Start up innovative 2018 D.G.R. 812/2018 - Asse 1 - Azione 1.4.1 POR-FESR 2014 - 2020
Prometheus is an innovative start-up that proposes Ematik, an innovative patented system consisting of a machine and a disposable kit, for the creation of an autologous and customised medicament for veterinary use, in particular for the treatment of hard-to-heal skin wounds.
In less than 50 minutes, the Ematik system allows the veterinarian to develop a tailor-made medicament by combining the patient's blood with the biopolymer mixture supplied with the disposable kit. Ematik, which can be used on animals of all sizes, is capable of accelerating and improving the healing of hard-to-heal skin wounds. The technological innovation, demonstrated by the results obtained from various clinical tests conducted on animals with chronic wounds, is given by:
- Healing times halved compared to competing products;
- Autologous personalised medicament (obtained from the patient's own blood) and with no side effects;
- Allows the reappearance of the animal's original fur without scarring (important aspect in high value animals);
- Antibacterial properties: reduces the risk of infection in the injured area and allows the use of antimicrobial/antibiotic substances to be reduced;
- Easy to apply and bio-absorbable from the wound;
- Fully automated and fast: Ematik, starting with the loading of the patient's blood into the machine, allows the production of an autologous and customised medicament in just 50 minutes.
By participating in the 2018 Start up call, Prometheus aimed to optimise IoT solutions and accelerate market penetration through the acquisition of:
- Machinery and technical equipment for the production process, furniture and hardware
- Rental and hire of scientific equipment and laboratories
- Promotional expenses for website, promotional material, advertising, promotional/scientific publications, participation in trade fairs
- Technical consultancy for product and equipment optimisation
- Strategic and IP protection consultancy
The implementation of the project enabled the achievement of the planned objectives
in particular: - enhancement of the company's IT equipment through the purchase of new hardware instruments
- enhancement of the technical and production equipment through the purchase of specific equipment and tools
- supporting investments in marketing, in particular for promotional material, participation in trade fairs (SCIVAC), implementation of a marketing campaign and optimisation of the website
- the acquisition of specialist technical consultancy, in particular for the optimisation of technical production equipment, hardware/software and aesthetic/functional optimisation of the Ematik machine and its industrialisation
- acquisition of specialist advice for the implementation of the sales network and for the protection of intellectual property by filing and extending patents abroad
